Showing 5541-5550 of 8888 results for "".
- Short Course Radiation Best Longer Courses in Older Skin Cancer Patientshttps://practicaldermatology.com/news/short-case-radiation-best-longer-courses-in-older-skin-cancer-patients/2457899/Shorter courses of radiation seem to be better than longer ones for older patients receiving treatment for basal and squamous cell skin cancers, a recent Penn State College of Medicine physician’s st
- Dove Launches DermaSeries Product Line for Dry Skin Plus Companion Campaignhttps://practicaldermatology.com/news/dove-launches-dermaseries-product-line-for-dry-skin-plus-companion-campaign/2457904/Dove is rolling out NEW Dove DermaSeries, a completely hypoallergenic and fragrance-free range of cleansers and lotions formulated especially for the driest skin. A companion campaign --
- Allergan Rolls Out "Not Cool vs. Cool"CoolSculpting Campaign Starring Professional Male Athlete Brand Ambassadorshttps://practicaldermatology.com/news/allergan-rolls-out-not-cool-vs-coolcoolsculpting-campaign-starring-professional-male-athlete-brand-ambassadors/2457905/Allergan’s new "Not Cool vs. Cool" Multi-Channel Campaign for CoolSculpting® stars Professional Athlete Brand Ambassadors: Figure Skater Johnny Weir and Go
- SkylineDx and Mayo Clinic To Collaborate on Development of Diagnostic Tests for Melanomahttps://practicaldermatology.com/news/skylinedx-and-mayo-clinic-to-collaborate-on-development-of-diagnostic-tests-for-melanoma/2457903/SkylineDx and Mayo Clinic are working together to develop novel diagnostic tests which will improve clinical decision making for melanoma patients. SkylineDx will help Mayo Clinic to optimize and further develop an algorithm to identify risk factor
- Amazon, Berkshire Hathaway, JPMorgan Chase Partner on Healthcarehttps://practicaldermatology.com/news/amazon-berkshire-hathaway-jpmorgan-chase-partner-on-healthcare/2457907/Amazon, Berkshire Hathaway, and JPMorgan Chase & Co. are partnering in an effort to seek solutions for delivering healthcare to their employees. The three companies will pursue this objective through an independent company that is free from profit-making incentives and constraints, they said
- Intraderm Changes Alevicyn Product Name to Levicynhttps://practicaldermatology.com/news/intraderm-changes-alevicyn-product-name-to-levicyn/2457910/Intraderm's Alevicyn is getting a new name—Levicyn. The Gel formulation is now Levicyn Antipruritic Gel, the Spray Gel is now Levicyn Antipruritic SG, and the Dermal Spray is now Levicyn Antimicrobial Dermal Spray. The company notes that physicians can still write for Alevicyn d
- Meet TempSure™ Envi from Hologic's Cynosure Divisionhttps://practicaldermatology.com/news/meet-tempsure-envi-from-hologics-cynosure-division/2457915/Hologic's Cynosure division is launching TempSure™ Envi – an FDA-cleared advanced radiofrequency device. TempSure™ Envi heats the deep layers of skin to regenerate collagen and impro
- Alastin Skincare Launches Restorative Neck Complexhttps://practicaldermatology.com/news/alastin-skincare-launches-restorative-neck-complex/2457916/Alastin Skincare, Inc. has incorporated its proven, proprietary TriHex Technology into a new product designed for the specific needs of the neck and décolletage: Restorative Neck Complexwith TriHex Technology. This breakthrough treatment is formulated to addr
- Maui Derm: New Data Validates First IGA Scale for EBS Clinical Trialshttps://practicaldermatology.com/news/maui-derm-new-data-validates-first-iga-scale-for-ebs-clinical-trials/2457923/Data from an evaluation of a completed Phase 2 study of diacerein 1% ointment (CCP-020) for the treatment of epidermolysis bullosa simplex (EBS) validate the first disease-specific Investigator’s Global Assessment (IGA) scale, Castle Creek Pharmaceuticals (CCP) reports at Maui Derm (
- Cochrane Review: Biologics Trump Other Systemics for Psohttps://practicaldermatology.com/news/cochrane-review-biologics-trump-other-systemic-meds-for-pso/2457924/Biologics appear to be the most effective systemic medicines for achieving a chronic plaque psoriasis score of PASI (Psoriasis Area and Severity Index) 90, according to a newly published Cochrane Revie